Rheumatology
| Lupus Nephritis
Rheumatology
Lupus Nephritis

Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis

book_2 Source: ACR Convergence 2020 - Oral session summaries - Abs #0988
calendar_today Published on Medfyle: November 2020
import_contacts 7 min
headphones 6 min

In this medfyle

Expert commentary by Laura Andreoli, MD, PhD

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Acknowledgements
Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the ACR Convergence 2020 and presented by:

Richard Furie, MD
Zucker School of Medicine at Hofstra/Northwell
Great Neck, NY, USA

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Laura Andreoli, MD, PhD
University of Brescia, Brescia, Italy

The content is produced by Infomedica, an approved ACR education partner. The summary text was drafted by Marie Farrow, and reviewed by Alessia Alunno, MD, PhD, an independent external expert, and approved by Atul Deodhar, MD, MRCP, the scientific editor of the program.
This activity is included in the ACR's Education Partner program. Independent reporting and the viewpoints expressed are those of Infomedica and its affiliates and do not represent the ACR.

About the Expert
Read more arrow_downward Hide arrow_upward

Laura Andreoli, MD, PhD
University of Brescia, Brescia, Italy
Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy

Professor Andreoli graduated in medicine in 2005. Since 2006, she has worked at the Pregnancy Clinic in Brescia, which is dedicated to the management of pregnancy in patients with inflammatory arthritis and systemic autoimmune diseases, and to the study of predictors of outcome and implications of the use of anti-rheumatic drugs (conventional and biologic) in pregnant patients. From 2010, she specialized in rheumatology at the University of Brescia, Italy, where she gained her PhD in the “Methodology of Clinical Research” in 2015. She worked as Assistant Professor of rheumatology between 2014 and 2019 and has been an Associate Professor of rheumatology at the University of Brescia since 2019. She is also a consultant physician for the Rheumatology and Clinical Immunology Unit of Spedali Civili in Brescia.

Professor Andreoli’s main interests include the pathogenesis, diagnosis and treatment of systemic autoimmune diseases, particularly systemic lupus erythematosus and antiphospholipid syndrome. Her research activity has been conducted within the framework of national/international networks. She is the author/co-author of nearly 150 publications in international journals indexed by PubMed and was the fellow in charge of literature reviews for EULAR Task Forces between 2014 and 2018, with a focus on SLE and the management of antiphospholipid syndrome in adults, including in pregnancy. These reviews have been promoted by EULAR. In 2018, the Italian Society for Rheumatology launched the “Italian Registry of Pregnancy in Rheumatic Diseases” (P-RHEUM.it) study, of which Professor Andreoli was co-PI (with Professor Angela Tincani).

References
Read more arrow_downward Hide arrow_upward

1. Tektonidou MG, Dasgupta A, Ward MM.Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol 2016;68(6):1432–41.


Feedback